Pemetrexed for the first-line treatment of non-small-cell lung cancer

NICE technology appraisals [TA181] Published date:

Pemetrexed is recommended as a possible treatment for locally advanced or metastatic non-small-cell lung cancer (NSCLC) if:

  • the cancer is a particular type (adenocarcinoma or large-cell carcinoma) and
  • the person has not had any treatment for NSCLC before.

Healthcare professionals should not stop prescribing pemetrexed for people who do not have adenocarcinoma or large-cell carcinoma who were already taking it when the guidance was issued. These people should be able to carry on taking pemetrexed until they and their specialist decide that it is the right time to stop treatment.

Get involved